ClinicalTrials.gg
Not yet recruitingNCT06971133Updated May 14, 2025

Causes of Secondary and Prolonged Fever During Treatment of Bacterial Meningitis and Viral Encephalitis

An observational study in Meningitis in Children and Encephalitis in Children, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
1 Month to 18 Years
Sex
All
01

Study summary

The aim of the present study is to investigate causes of secondary and prolonged fever during treatment of viral encephalitis and bacterial meningitis in children aged from one month to 18 years .

Read the detailed description

Fever is a common symptom in both viral encephalitis and bacterial meningitis. However, in some patients, fever may persist or recure during the course of treatment. This can be concerning and may indicate unresolved infection, secondary infections, inflammatory responses, or treatment complications. Understanding the underlying causes and adopting a structured approach to management is crucial for improving patient care. Prolonged fever means fever persisting beyond 8-10 days despite appropriate treatment. Secondary fever means fever occurring after an initial period of defervescence, meaning the fever had initially subsided for at least 48 hours before recurring or a new fever spike following an apparent resolution. The common and established causes of secondary and prolonged fever in pediatrics patients during the treatment of bacterial meningitis and viral encephalitis include, nosocomial infections, subdural effusion, phlebitis, pneumonia , drug fever, otitis media, gastroenteritis and urinary tract infection . Subdural effusion prolongs fever in patients with meningitis. It occurs as a complication due to persistent inflammation, secondary infection, or inadequate resolution of the infection within the subdural space. Urinary tract infections (especially in catheterized patients) is nosocomial or superimposed infections that cause secondary or prolonged fever in pediatric patients during the treatment of meningitis or encephalitis. Otitis media can cause secondary or prolonged fever during the treatment of meningitis and encephalitis in pediatric patients. This can occur due to persistent infection, suppurative complications (such as mastoiditis or subdural empyema), or an inadequate response to initial antimicrobial therapy. Pneumonia, including hospital-acquired pneumonia, can cause secondary or prolonged fever during the treatment of CNS infections in pediatric patients. This occurs due to superimposed bacterial infections, ventilator-associated pneumonia in critically ill children, or aspiration pneumonia in patients with neurological compromise. Gastro-entritis can occur in hospitalized children undergoing treatment for CNS infections due to concurrent infections, dehydration-related metabolic disturbances, or systemic inflammatory responses. Enteric pathogens such asRotavirus, Norovirus, or bacterial causes like Salmonella and Clostridioides difficile can contribute to prolonged fever in hospitalized children undergoing treatment for CNS infections. Phlebitis can cause secondary fever during the treatment of encephalitis and meningitis in pediatric patients. It is often associated with intravenous catheter use, leading to localized or systemic infections, including catheterrelated bloodstream infections, which can contribute to persistent or recurrent fever.

Drug fever is a well-recognized phenomenon where fever arises as an adverse reaction to medications, often without an identifiable infectious source. It typically resolves upon discontinuation of the offending drug. In the context of meningitis and encephalitis treatment, antibiotics (e.g., beta-lactams, sulfonamides, vancomycin), anticonvulsants, and antipyretics have been implicated. A relapse of encephalitis or meningitis occurs due to incomplete eradication of the infection, emergence of resistant pathogens, or host immune deficiencies. This can lead to persistent inflammation, ongoing infection, or secondary complications such as subdural effusion or vasculitis, which contribute to prolonged or recurrent fever.

02

Conditions studied

  • Meningitis in Children
  • Encephalitis in Children
03

In context

Encephalitis

125 studies on the registry are indexed under Encephalitis; 33 are open to participants now.

This study's planned enrollment of 50 is below the median of 300 across 54 observational studies indexed under Encephalitis.

Browse Encephalitis studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Included children aged from one month to 18 years , who were diagnosed as bacterial meningitis or viral encephalitis and admitted to neurological department at AUCH and develop secondary or prolonged fever despite appropriate treatment .

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children from one month to 18 years.
  • Who were diagnosed with bacterial meningitis or viral encephalitis and admitted to neurological department at Assiut University Children's Hospital (AUCH).
  • Develop secondary or prolonged fever despite appropriate treatment.

Exclusion criteria

Exclusion Criteria:

  • Pediatric patients with suspected encephalitis.
  • Patient on therapy (e.g., post-organ transplant, chemotherapy).
  • Pediatric patients suspected metabolic disorders.
  • Those with suspected endocrine dysfunction.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Causes of secondary and prolonged fever during treatment of bacterial meningitis and viral encephalitis

    Causes of secondary and prolonged fever during treatment of bacterial meningitis and viral encephalitis

    Time frame: Basline

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Brouwer MC, McIntyre P, de Gans J, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2010 Sep 8;(9):CD004405. doi: 10.1002/14651858.CD004405.pub3. PubMed 20824838 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for Apr 2026, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2025
First posted
May 14, 2025
StartEst.
May 2025
Primary completionEst.
Apr 2026
CompletionEst.
May 2026
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06971133
Lead sponsor
Assiut University
Responsible party
Kerolos Atef Shafeek Tanious (Doctor, Assiut University) — Principal investigator
First posted
May 14, 2025
Start date
May 2025 (estimated)
Primary completion
Apr 2026 (estimated)
Completion
May 2026 (estimated)
Last update
May 14, 2025

Study contacts

Kerolos Atef Shafeek Tanious
Contact
keroatef743@gmail.com
+201278046794
Prof. Mostafa Shafeek Khalaf Tawfeek, Professor of Pediatrics
principal investigator · Assiut University
Dr. Khalaf Abd El-Aal Sayed Mohamed, Lecturer of Pediatrics
principal investigator · Assiut University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion